OTCMKTS:RHHBY Roche (RHHBY) Stock Price, News & Analysis $54.91 +0.24 (+0.44%) As of 09:53 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesInsider TradesOwnershipShort InterestBuy This Stock About Roche Stock (OTCMKTS:RHHBY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roche alerts:Sign Up Key Stats Today's Range$54.74▼$55.2750-Day Range$49.00▼$56.5252-Week Range$37.51▼$60.85Volume126,721 shsAverage Volume2.36 million shsMarket Capitalization$349.81 billionP/E RatioN/ADividend Yield1.77%Price Target$51.50Consensus RatingHold Company Overview Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY). In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies. The diagnostics business supplies a broad range of in vitro and molecular diagnostics, tissue‑based pathology solutions, point‑of‑care testing and diabetes care products, along with instruments and assay systems used by hospitals, laboratories and clinics to support clinical decision‑making and patient monitoring. Roche has a global footprint with operations and research facilities across Europe, the Americas and Asia, and a portfolio that combines internally developed products with offerings from affiliated biotech subsidiaries. The company emphasizes research and development and partnerships to advance precision medicine, leveraging its diagnostics expertise to support the selection and monitoring of appropriate therapies.AI Generated. May Contain Errors. Read More Roche Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreRHHBY MarketRank™: Roche scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingHold Consensus RatingRoche has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.Downside RiskRoche has a consensus price target of $51.50, representing about 6.1% downside from its current price of $54.85.Amount of Analyst CoverageRoche has only been the subject of 2 research reports in the past 90 days.Read more about Roche's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.54% Earnings GrowthEarnings for Roche are expected to grow by 7.54% in the coming year, from $3.05 to $3.28 per share.Price to Earnings Growth RatioRoche has a PEG Ratio of 4.04. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoche has a P/B Ratio of 7.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Roche has been sold short.Short Interest Ratio / Days to CoverRoche has a short interest ratio ("days to cover") of 0.94, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Roche has recently decreased by 11.50%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRoche pays a meaningful dividend of 1.76%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoche does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Roche will have a dividend payout ratio of 29.57% next year. This indicates that Roche will be able to sustain or increase its dividend.Read more about Roche's dividend. News and Social Media2.7 / 5News Sentiment0.33 News SentimentRoche has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Roche this week, compared to 7 articles on an average week.Search Interest8 people have searched for RHHBY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added Roche to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Roche insiders have not sold or bought any company stock.Percentage Held by InstitutionsRoche has minimal institutional ownership at this time.Read more about Roche's insider trading history. Receive RHHBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RHHBY Stock News HeadlinesFY2026 EPS Estimates for Roche Reduced by Erste Group BankAugust 2 at 1:29 AM | americanbankingnews.comRoche receives FDA clearance for cobas BV/CV assay, expanding women’s health diagnosticsJuly 24, 2026 | msn.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 3 at 1:00 AM | Altimetry (Ad)How Roche unexpectedly buoyed IBD stock of the day, TG TherapeuticsJuly 24, 2026 | msn.comRoche Holding AG (RHHBY) Q2 2026 Earnings Call TranscriptJuly 24, 2026 | seekingalpha.comRoche jumps despite reiterated 2026 outlookJuly 23, 2026 | msn.comRoche Backs Full-Year View as First-Half Sales RiseJuly 23, 2026 | wsj.comRoche confirms full year targets as first-half sales fallJuly 23, 2026 | reuters.comSee More Headlines RHHBY Stock Analysis - Frequently Asked Questions How have RHHBY shares performed this year? Roche's stock was trading at $51.57 at the beginning of 2026. Since then, RHHBY stock has increased by 6.4% and is now trading at $54.85. Does Roche have any subsidiaries? The following companies are subsidiaries of Roche: Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and others. Who are Roche's major shareholders? Top institutional shareholders of Roche include GAMMA Investing LLC, Confluence Investment Management LLC and Fulton Bank N.A.. How do I buy shares of Roche? Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:RHHBY CIKN/A Webwww.roche.com Phone(161) 688-1111Fax41-0-61-691-9391Employees103,249Year Founded1896Price Target and Rating Average Price Target for Roche$51.50 High Price Target$57.00 Low Price Target$46.00 Potential Upside/Downside-5.8%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio17.92 P/E Growth4.04Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.72 Current Ratio1.38 Quick Ratio1.12 Sales & Book Value Annual Sales$76.45 billion Price / Sales4.56 Cash Flow$3.60 per share Price / Cash Flow15.18 Book Value$7.18 per share Price / Book7.61Miscellaneous Outstanding Shares6,370,538,000Free FloatN/AMarket Cap$348.28 billion OptionableNot Optionable Beta0.50 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:RHHBY) was last updated on 8/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.